As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
14 Analysts have issued a Pharming Group N.V. - ADR forecast:
14 Analysts have issued a Pharming Group N.V. - ADR forecast:
Jun '25 |
+/-
%
|
||
Revenue | 340 340 |
22%
22%
|
|
Gross Profit | 304 304 |
23%
23%
|
|
EBITDA | 40 40 |
10,976%
10,976%
|
EBIT (Operating Income) EBIT | 25 25 |
249%
249%
|
Net Profit | -8.20 -8.20 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Head office | Netherlands |
CEO | Fabrice Chouraqui |
Employees | 404 |
Founded | 1988 |
Website | www.pharming.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.